Nutra Pharma Corp (NPHC) Amortization of Deferred Charges (2015 - 2019)

Nutra Pharma has disclosed Amortization of Deferred Charges across 5 years of filings, most recently posting $5090.0 for Q3 2019.

• In Q3 2019, Amortization of Deferred Charges fell 99.91% year-over-year to $5090.0; the TTM figure through Sep 2019 stood at -$5.5 million (down 198.82% YoY), while the FY2018 annual figure was $32146.0, up 11.56% from the prior year.
• Amortization of Deferred Charges came in at $5090.0 for Q3 2019 at Nutra Pharma, up from $4688.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $5.5 million in Q3 2018 to a low of -$5.5 million in Q4 2018.
• Average Amortization of Deferred Charges over 5 years is $16684.4, with a median of $9887.0 recorded in 2018.
• The largest YoY upside for Amortization of Deferred Charges was 61110.61% in 2018 against a maximum downside of 36674.61% in 2018.
• Over 5 years, Amortization of Deferred Charges stood at $49250.0 in 2015, then advanced by 1.24% to $49861.0 in 2016, then plunged by 69.92% to $15000.0 in 2017, then tumbled by 36674.61% to -$5.5 million in 2018, then surged by 100.09% to $5090.0 in 2019.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $5090.0 in Q3 2019, $4688.0 in Q2 2019, and $8147.0 in Q1 2019.